Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.59 |
| ▸ | CA2 | P00918 | 17/20 | 0.59 |
| ▸ | CA12 | O43570 | 14/20 | 0.59 |
| ▸ | CA9 | Q16790 | 14/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406399 | 0.79 | — | — | |
| Benzenesulfonamide SCHEMBL729 | 0.77 | CA2 (1.00) | CA1CA2CA12CA9CA7 | |
| SCHEMBL19479299 | 0.77 | CA2 (1.00) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL6868390 | 0.77 | CA2 (1.00) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL1332409 | 0.77 | CA2 (1.00) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL28257999 | 0.77 | CA2 (1.00) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL29825137 | 0.77 | CA2 (1.00) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL1009443 | 0.75 | CA2 (0.94) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL3056735 | 0.75 | CA2 (0.94) | CA1CA2CA12CA9CA7 | |
| Benzenesulfonamide SCHEMBL3100364 | 0.75 | CA2 (0.94) | CA1CA2CA12CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541475-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| CN-101300006-B | MAO-B inhibitors useful for treating obesity | DISCOVERY JENRIN | 2012-07-25 | — | — | CN | disclosed |
| US-20100168068-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2010-07-01 | — | — | US | disclosed |
| US-7649115-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| CN-101300006-A | MAO-B inhibitors useful for treating abesity | DISCOVERY JENRIN (US) | 2008-11-05 | — | — | CN | disclosed |
| EP-1890690-A2 | MAO-B INHIBITORS USEFUL FOR TREATING ABESITY | Jenrin Discovery (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070088004-A1 | Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); | JENRIN DISCOVERY, INC. | 2007-04-19 | — | — | US | disclosed |
| WO-2006130707-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088004-A1 | Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); | MAOB, MAOA, APOB | CA1 4838/4885CA2 3532/4885CA12 4764/4885 |
| US-20100168068-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | CA1 4802/4885CA2 3637/4885CA12 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.